BeiGene(688235) 东吴证券·2024-11-17 10:48Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has experienced rapid revenue growth, with total revenue reaching 750 million, 1.000 billion respectively, with Q3 showing a quarter-on-quarter increase of 7.6%. The European and American markets contributed over 76% of the revenue. The global sales of Zebutinib reached 504 million (+87%) and European sales at 167 million (+16%) [2][3] Financial Forecast and Valuation - The company is projected to achieve revenues of 255.3 billion yuan, 340.6 billion yuan, and 423.8 billion yuan for the years 2024, 2025, and 2026 respectively. The continuous high growth in sales of core products and the opening of overseas markets indicate a high certainty of growth, leading to the maintained "Buy" rating [4]